Research graph
References from Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1056/nejmra1713263
10.1056/nejmra1713263 · External reference
10.1007/s10620-019-05515-8
10.1007/s10620-019-05515-8 · External reference
Unresolved reference
External reference
10.1038/s41572-020-00240-3
10.1038/s41572-020-00240-3 · External reference
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept
10.1038/s41598-018-28337-6 · 2018 · External reference
The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma
10.1097/cad.0000000000001202 · 2022 · External reference
Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments
10.1016/j.tranon.2021.101201 · 2021 · External reference
10.1016/s1470-2045(08)70285-7
10.1016/s1470-2045(08)70285-7 · External reference
10.1056/nejmoa0708857
10.1056/nejmoa0708857 · External reference
10.1016/s0140-6736(18)30207-1
10.1016/s0140-6736(18)30207-1 · External reference
10.1016/s0140-6736(17)31046-2
10.1016/s0140-6736(17)31046-2 · External reference
10.1056/nejmoa1915745
10.1056/nejmoa1915745 · External reference
10.1016/j.ctarc.2021.100328
10.1016/j.ctarc.2021.100328 · External reference
Comprehensive and integrative genomic characterization of hepatocellular carcinoma
10.1016/j.cell.2017.05.046 · 2017 · External reference
Mutations in NOTCH1 and nucleotide excision repair genes are correlated with prognosis of hepatitis B virus-associated hepatocellular carcinoma
10.7150/jca.25438 · 2018 · External reference
10.1053/gast.2001.24798
10.1053/gast.2001.24798 · External reference
10.1158/0008-5472.can-03-2320
10.1158/0008-5472.can-03-2320 · External reference
Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets
10.1053/j.gastro.2004.09.015 · 2004 · External reference
10.1002/pros.20803
10.1002/pros.20803 · External reference
10.1093/nar/gkm797
10.1093/nar/gkm797 · External reference
10.1038/ng1481
10.1038/ng1481 · External reference
10.1006/excr.2000.5146
10.1006/excr.2000.5146 · External reference
10.1093/nar/gkl845
10.1093/nar/gkl845 · External reference
10.1038/ng1490
10.1038/ng1490 · External reference
10.1093/carcin/21.3.371
10.1093/carcin/21.3.371 · External reference
Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability
10.1155/2013/931972 · 2013 · External reference
10.1186/1471-2164-11-s4-s19
10.1186/1471-2164-11-s4-s19 · External reference
10.1016/j.jhep.2009.11.005
10.1016/j.jhep.2009.11.005 · External reference
Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma
10.1007/s00432-007-0316-8 · 2008 · External reference
Binding of wild-type p53 by topoisomerase II and overexpression of topoisomerase II in human hepatocellular carcinoma
10.1006/bbrc.1997.6539 · 1997 · External reference
10.1002/hep.23540
10.1002/hep.23540 · External reference
10.1016/j.jhep.2003.10.008
10.1016/j.jhep.2003.10.008 · External reference
10.1016/0006-2952(94)00515-n
10.1016/0006-2952(94)00515-n · External reference
Prognostic prediction and treatment strategy in hepatocellular carcinoma
10.1053/jhep.2002.32089 · 2002 · External reference
Diabetes mellitus is a recurrence-independent risk factor in patients with hepatitis B virus-related hepatocellular carcinoma undergoing resection
10.1097/00042737-200311000-00009 · 2003 · External reference
Nodules less than 20 mm and vascular invasion are predictors of survival in small hepatocellular carcinoma
10.1097/mcg.0b013e31817ff199 · 2009 · External reference
10.1038/bjc.2012.559
10.1038/bjc.2012.559 · External reference
PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation
10.1016/j.jss.2013.05.016 · 2013 · External reference
A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo
10.1186/1471-2407-13-527 · 2013 · External reference
Gold nanoparticles-loaded anti-miR221 enhances antitumor effect of sorafenib in hepatocellular carcinoma cells
10.7150/ijms.37427 · 2019 · External reference
Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F–1
10.1007/s00280-013-2120-2 · 2013 · External reference
Lysyl oxidase assists tumor-initiating cells to enhance angiogenesis in hepatocellular carcinoma
2019 · External reference
AKR1B10 inhibitor enhances the inhibitory effect of sorafenib on liver cancer xenograft
2019 · External reference
Anti-GPC3 antibody tagged cationic switchable lipid-based nanoparticles for the co-delivery of anti-miRNA27a and sorafenib in liver cancers
10.1007/s11095-019-2669-5 · 2019 · External reference
SLC27A5 deficiency activates NRF2/TXNRD1 pathway by increased lipid peroxidation in HCC
10.1038/s41418-019-0399-1 · 2020 · External reference
Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide
10.1158/1078-0432.ccr-12-3306 · 2013 · External reference
Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals
10.1038/cddis.2017.411 · 2017 · External reference
10.1096/fj.201700306rr
10.1096/fj.201700306rr · External reference
Synergistic effect of sorafenib and vitamin K on suppression of hepatocellular carcinoma cell migration and metastasis
2015 · External reference
PCK1 downregulation promotes TXNRD1 expression and hepatoma cell growth via the Nrf2/Keap1 pathway
10.3389/fonc.2018.00611 · 2018 · External reference
Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma
10.1111/liv.14048 · 2019 · External reference
Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30
10.1111/cas.12885 · 2016 · External reference
Antitumor activity of the microtubule inhibitor MBRI-001 against human hepatocellular carcinoma as monotherapy or in combination with sorafenib
10.1007/s00280-018-3547-2 · 2018 · External reference
Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model
10.1593/neo.09664 · 2009 · External reference
10.1136/gutjnl-2016-312268
10.1136/gutjnl-2016-312268 · External reference
10.1007/s10620-014-3058-x
10.1007/s10620-014-3058-x · External reference
Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib
10.1002/hep.26425 · 2013 · External reference
Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma
2020 · External reference
10.3390/cancers11111646
10.3390/cancers11111646 · External reference
10.1016/j.semcancer.2010.10.011
10.1016/j.semcancer.2010.10.011 · External reference
10.1074/jbc.m204204200
10.1074/jbc.m204204200 · External reference
10.1042/bj3470089
10.1042/bj3470089 · External reference
10.1038/sj.onc.1202738
10.1038/sj.onc.1202738 · External reference
10.1158/0008-5472.can-16-1559
10.1158/0008-5472.can-16-1559 · External reference
Identification of hepatocellular carcinoma-related potential genes and pathways through bioinformatic-based analyses
10.1089/gtmb.2019.0063 · 2019 · External reference
10.1016/j.jss.2011.04.004
10.1016/j.jss.2011.04.004 · External reference
10.1016/s1470-2045(18)30351-6
10.1016/s1470-2045(18)30351-6 · External reference
10.1038/s41575-019-0186-y
10.1038/s41575-019-0186-y · External reference
10.1016/j.ccell.2020.07.004
10.1016/j.ccell.2020.07.004 · External reference
10.1002/hep.25956
10.1002/hep.25956 · External reference
10.1158/2159-8290.cd-13-0782
10.1158/2159-8290.cd-13-0782 · External reference
10.1016/j.cell.2006.05.030
10.1016/j.cell.2006.05.030 · External reference
10.1073/pnas.1811029115
10.1073/pnas.1811029115 · External reference
A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets
2019 · External reference
Identifying novel biomarkers in hepatocellular carcinoma by weighted gene co-expression network analysis
2019 · External reference
10.1096/fj.201802213rr
10.1096/fj.201802213rr · External reference
Aberrant expression of cell cycle and material metabolism related genes contributes to hepatocellular carcinoma occurrence
10.1016/j.prp.2017.01.019 · 2017 · External reference
Non-SMC Condensin I Complex, Subunit G (NCAPG) is a novel mitotic gene required for hepatocellular cancer cell proliferation and migration
10.3727/096504017x15075967560980 · 2018 · External reference
NCAPG promotes the proliferation of hepatocellular carcinoma through PI3K/AKT signaling
10.2147/ott.s217916 · 2019 · External reference
Two major alternative splice variants of beta-TrCP1 interact with CENP-W with different binding preferences
10.1007/s13258-018-0748-3 · 2019 · External reference
Cancer upregulated gene 2 (CUG2), a novel oncogene, promotes stemness-like properties via the NPM1-TGF-beta signaling axis
10.1016/j.bbrc.2019.05.091 · 2019 · External reference
10.1200/jco.2011.37.6418
10.1200/jco.2011.37.6418 · External reference
10.1038/nrclinonc.2012.245
10.1038/nrclinonc.2012.245 · External reference
HDAC inhibitors augmented cell migration and metastasis through induction of PKCs leading to identification of low toxicity modalities for combination cancer therapy
10.1158/1078-0432.ccr-12-0633 · 2012 · External reference
10.1093/nar/gks1193
10.1093/nar/gks1193 · External reference
10.1038/nature08987
10.1038/nature08987 · External reference
10.1093/nar/gkv1507
10.1093/nar/gkv1507 · External reference
Unresolved reference
2019 · External reference
Analysis of microarray data using Z score transformation
10.1016/s1525-1578(10)60455-2 · 2003 · External reference
10.1073/pnas.0506580102
10.1073/pnas.0506580102 · External reference
10.1593/neo.11222
10.1593/neo.11222 · External reference
